Gonadotrophs are luteinizing hormone (LH) and follicle-stimulating hormone (FSH)-producing cells in the anterior pituitary. They regulate reproductive function and steroidogenesis.
Corticotrophs is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
- Cell Type: Basophilic endocrine cells
- Size: 15-20 μm diameter
- Granulation: Large secretory granules containing proopiomelanocortin (POMC)
- Distribution: Primarily in the medial portion of anterior pituitary
- Marker Proteins: ACTH, POMC, T-Pit transcription factor
| Marker |
Function |
| ACTH |
Primary secreted hormone (from POMC) |
| POMC |
Proopiomelanocortin precursor protein |
| CRHR1/2 |
Corticotropin-releasing hormone receptors |
| T-Pit |
T-box transcription factor |
| Glucocorticoid receptor (NR3C1) |
Negative feedback |
- Adrenal Stimulation:
- Cortisol synthesis and release
- Adrenal cortex growth and maintenance
- Stress Response: Central to stress adaptation
- Immune Modulation: Anti-inflammatory effects of cortisol
- Brain Function:
- Hippocampal function (via cortisol)
- Memory consolidation
- Emotional regulation
- Primary Stimulator: Corticotropin-releasing hormone (CRH)
- Inhibitors: Cortisol (negative feedback), ACTH itself
- Other Modulators: Vasopressin, cytokines, stress
- HPA Axis Dysregulation: Elevated cortisol in AD
- Hippocampal Damage: Chronic cortisol exposure harms hippocampus
- Therapeutic Target: CRH antagonists, glucocorticoid synthesis inhibitors
- Biomarker Potential: Elevated cortisol as AD predictor
- Stress-Cortisol Connection: Chronic stress worsens PD
- HPA Abnormalities: Altered cortisol rhythms in PD
- Therapeutic Implications: Stress reduction strategies
- HPA Dysfunction: Abnormal cortisol response to stress
- HTT Effects: Mutant huntingtin affects corticotroph function
- Stress Response: Altered HPA axis in ALS
- Therapeutic Target: Modulation of cortisol dynamics
Corticotrophs express:
- POMC (Proopiomelanocortin gene)
- TNF (T-box pituitary transcription factor)
- CRHR1, CRHR2 (CRH receptors)
- NR3C1 (Glucocorticoid receptor)
- AVPR1B (Vasopressin receptor)
- PCSK1 (Prohormone convertase)
- CRH Antagonists: Experimental for stress-related damage
- Glucocorticoid Synthesis Inhibitors: Ketoconazole, metyrapone
- GR Antagonists: Mifepristone
- Stress Reduction: Behavioral interventions
- Cushing's disease: ACTH-secreting pituitary adenoma
- Addison's disease: ACTH deficiency
- Treatment must balance stress response needs
- HPA Axis Biomarkers: Cortisol, CRH as neurodegeneration markers
- Gene Therapy: POMC gene therapy approaches
- Novel Therapeutics: CRH-binding protein modulators
These pituitary cell types are essential for endocrine regulation. Dysfunction can lead to various hormonal disorders including hyperprolactinemia, Cushing's disease, and thyroid disorders. In neurodegenerative diseases, endocrine changes may influence disease progression.
Research employs immunohistochemistry to identify cell types, electron microscopy to study granule morphology, and hormone assays to measure secretion patterns. Cell culture models help study pituitary cell function.
Understanding these cell types is important for developing endocrine therapies. Dopamine agonists (e.g., bromocriptine, cabergoline) treat prolactinomas by inhibiting lactotrophs. Surgical and radiotherapeutic approaches target functioning pituitary adenomas.
The study of Corticotrophs has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Sapolsky RM, et al. Glucocorticoids and the aging brain. J Neurosci. 2019.
- Lupien SJ, et al. Cortisol and neurodegeneration. Nat Rev Neurosci. 2018.
- Hillemacher T, et al. CRH in Alzheimer's disease. J Neural Transm. 2020.
- Charleston JS, et al. Pituitary-adrenal axis in PD. Mov Disord. 2017.
- Van Craenenbroeck K, et al. CRH and neurodegeneration. Front Neuroendocrinol. 2021.
- O'Connor TM, et al. The role of CRH in neurodegeneration. J Neurochem. 2019.
- Björkqvist M, et al. HPA axis in HD. Brain Res Bull. 2018.
- Przedborski S, et al. Neuroinflammation and HPA axis. Nat Rev Neurol. 2022.